Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novocure Ltd NVCR

Healthcare Medical Devices
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and... see more

Recent & Breaking News (NDAQ:NVCR)

CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma

Business Wire September 19, 2016

Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine

Business Wire September 15, 2016

Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields

Business Wire September 14, 2016

10 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  September 12, 2016

A Peek Into The Markets: Dow Futures Tumble Over 100 Points

Benzinga.com  September 12, 2016

Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Superior Progression Free and Overall Survival Seen in the Trial’s Interim Analysis

Business Wire September 12, 2016

International Journal of Cancer Publishes Data Showing Tumor Treating Fields in Combination with Paclitaxel is Therapeutically Effective against Ovarian Cancer Cells in Vitro and in Vivo

Business Wire September 1, 2016

Novocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13

Business Wire August 16, 2016

Novocure to Present at Upcoming Investor Conferences

Business Wire August 8, 2016

18 Biggest Mid-Day Losers For Thursday

Benzinga.com  July 28, 2016

Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update

Business Wire July 28, 2016

Novocure to Host Research and Development Day on Dec. 12, 2016

Business Wire July 28, 2016

NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma

Business Wire July 26, 2016

Novocure Receives FDA Approval for Second Generation Optune System

Business Wire July 13, 2016

Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors

Business Wire June 30, 2016

Novocure to Report Second Quarter 2016 Financial Results

Business Wire June 30, 2016

Novocure to Present at JMP Securities 2016 Life Sciences Conference

Business Wire June 8, 2016

Novocure Receives IDE Approval to Initiate METIS Trial

Business Wire May 31, 2016